In the case of CD36, uc.372 binds to the terminal loop region of pri-miR-4668, blocking its maturation and relieving its gene silencing effect on CD36. Because uc.372 promotes hepatic steatosis through these mechanisms, uc.372 inhibitors could be potential therapeutic agents for NAFLD. The gene discussed is CD36; the disease is Hepatic steatosis.